Related Experiment Videos
Octreotide and postoperative enterocutaneous fistulae: a controlled prospective study
N A Scott1, S Finnegan, M H Irving
1University Department of Surgery, Salford, United Kingdom.
Acta Gastro-Enterologica Belgica
|May 1, 1993
Summary
Octreotide did not significantly reduce fluid loss from enterocutaneous fistulae in a 12-day trial. This study found no significant difference in fistula output or closure rates between octreotide and placebo treatments.
Area of Science:
- Gastroenterology
- Surgical Outcomes
Background:
- Postoperative enterocutaneous fistulae present a significant clinical challenge.
- Effective management strategies for these fistulae are crucial to improve patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of octreotide in managing postoperative enterocutaneous fistulae.
- To assess octreotide's impact on fistula output and spontaneous closure rates.
Main Methods:
- A double-blind, randomized controlled trial involving 19 patients with enterocutaneous fistulae.
- Patients received either 12 days of subcutaneous octreotide (100 micrograms tds) or placebo injections.
- Fistula output was meticulously recorded for 7 days pre-treatment and throughout the 12-day treatment period.
Main Results:
- Baseline fistula output was comparable between the octreotide and placebo groups.
- No statistically significant difference in daily fistula output was observed between the octreotide and placebo treatment arms.
- Spontaneous fistula closure occurred in only 1 patient receiving octreotide versus 3 patients in the placebo group.
Conclusions:
- Octreotide therapy, administered subcutaneously for 12 days, did not demonstrate a significant reduction in fistula output for enterocutaneous fistulae.
- The study found no evidence that octreotide enhances the spontaneous closure rate of these fistulae compared to placebo.